This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
15 Apr 2019

Hovione Technology acquires global rights to new pulmonary inhaler device

Papillon - multi-use blister DPI.

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Hovione Technology has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler (DPI) patented by inventor Dr Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.

The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at global scale.
Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.
Hovione Technology’s CEO Peter Villax said: “This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI”.
Hovione Technology has a co-promotional agreement with API manufacturer Hovione and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.

Mentioned Companies
Hovione FarmaCiencia SA
View company profile

Related News